Is It Safe to Take Ivermectin Long-Term?
Written by Dr. Daniel Foster, Men's Health, Urology & Sexual Wellness Content Specialist
Reviewed for medical accuracy under the Ivermectinkart Editorial Policy
Introduction
Whether it is safe to take ivermectin long-term depends heavily on what “long-term” means, why the medicine is being used, and how often it is taken. Ivermectin has a long history of repeated use for certain parasitic diseases, including programs in which people receive a supervised dose every 6 or 12 months for many years. That experience is very different from taking ivermectin every day or every week indefinitely, for which long-term safety evidence is much more limited. In the United States, oral ivermectin is a prescription antiparasitic medicine approved for intestinal strongyloidiasis and onchocerciasis, and its usual treatment schedules are not continuous daily therapy. Repeated or prolonged treatment is appropriate in some special medical situations, but it should be directed by a clinician who understands the infection, other medicines being taken, and potential adverse effects. This article explains what long-term ivermectin use can mean, when repeated treatment is medically established, what risks are known, and why unsupervised chronic use is a different safety question.
What Does “Long-Term Ivermectin Use” Actually Mean?
Long-term ivermectin use can describe several very different treatment patterns. A person receiving one dose each year for a parasitic infection is not exposed to the medicine in the same way as someone taking tablets every day for months.
This distinction is essential when discussing safety.
The current U.S. ivermectin prescribing information describes a single oral dose for uncomplicated intestinal strongyloidiasis and a single dose followed by retreatment when necessary for onchocerciasis. In international onchocerciasis programs, a 12-month treatment interval is commonly used, although individual patients may sometimes be retreated sooner.
Different ivermectin-use patterns should not be treated as equivalent
Pattern of Use | Example | What the Evidence Tells Us |
Short treatment | One or a few doses for an appropriate parasitic infection | Well established for approved or guideline-supported indications |
Intermittent repeated treatment | A supervised dose every 6–12 months for onchocerciasis | Extensive public-health experience exists |
Repeated treatment for persistent infection | Additional courses for documented strongyloidiasis | Sometimes medically necessary, particularly in complicated cases |
Suppressive treatment | Selected immunocompromised patients with difficult extra-intestinal strongyloidiasis | May be considered under specialist supervision; optimal regimen is not well established |
Frequent daily or weekly use for months or years | Chronic self-treatment without a defined parasitic indication | Long-term safety and benefit are not adequately established |
The last category is where much of the uncertainty lies. Evidence from annual mass-treatment programs cannot simply be used to conclude that frequent or continuous ivermectin exposure is equally safe.
Years of intermittent ivermectin treatment do not equal years of continuous ivermectin use. A person receiving one medically supervised dose every six or twelve months has a very different exposure pattern from someone taking ivermectin every day or every week.
Is Ivermectin Long-Term Use Ever Recommended?
Yes, repeated ivermectin treatment is medically established for certain parasitic infections. However, treatment frequency is determined by the parasite and clinical situation rather than by a general rule that ivermectin can safely be taken indefinitely.
Repeated treatment for onchocerciasis
Onchocerciasis, also called river blindness, provides the clearest example of long-term intermittent treatment.
The WHO guidance on onchocerciasis treatment recommends ivermectin at least once yearly for 10–15 years in affected communities because the drug kills immature worms but does not reliably eliminate the long-lived adult parasite.
CDC similarly describes treatment every six months for as long as an infected person continues to have evidence of skin or eye infection.
This extensive experience shows that repeated, appropriately spaced ivermectin treatment can be used over long periods when there is a genuine parasitic indication.
It does not demonstrate that continuous dosing is necessary or beneficial. CDC specifically states that prolonged daily ivermectin treatment for onchocerciasis has not been shown to provide an advantage over periodic treatment and that higher-than-recommended doses can increase adverse effects.
Repeated treatment for strongyloidiasis
Uncomplicated intestinal strongyloidiasis is usually treated with a short course rather than indefinite ivermectin.
The CDC Strongyloides treatment guidance recommends ivermectin as first-line therapy for acute or chronic uncomplicated strongyloidiasis, with follow-up when infection persists. Severe disseminated infection is different: ivermectin may be given daily until stool and sputum examinations remain negative for two weeks.
The U.S. drug label also notes that immunocompromised patients may occasionally require repeated courses and that monthly suppressive therapy may help in difficult extra-intestinal disease. Importantly, the label states that adequate controlled studies have not established an optimal regimen in these patients.
That is a specialist treatment situation—not a recommendation for routine long-term self-medication.
What Are the Risks of Taking Ivermectin Repeatedly?
Ivermectin is generally well tolerated when used at appropriate doses for established indications, but it is not free of adverse effects. Increasing the dose, taking it more frequently, or continuing treatment without a medical reason can expose a person to risk without proven additional benefit.
Common or less severe adverse effects
Clinical trials and post-marketing experience have reported effects such as:
Dizziness
Nausea or vomiting
Diarrhea
Fatigue
Itching
Rash
Swelling
Headache
Low blood pressure in some patients
Some reactions during treatment for onchocerciasis result partly from the immune response to dying parasites rather than from direct drug toxicity.
Neurological effects can occur
The current U.S. label warns that neurotoxicity has been reported, including marked sleepiness, confusion, disorientation, stupor, coma, and, rarely, death. Such reports are uncommon, but they are important when considering unnecessary repeated exposure.
Large doses are particularly concerning.
The FDA information on ivermectin safety warns that ivermectin overdose can cause nausea, vomiting, diarrhea, low blood pressure, problems with balance, seizures, coma, and death. The FDA also stresses that veterinary ivermectin products should never be used in people.
Liver effects have been reported
Post-marketing reports include hepatitis and elevations in liver enzymes and bilirubin.
These reports do not mean that everyone taking ivermectin requires routine liver testing after a standard short treatment. They do mean that unexplained jaundice, dark urine, significant abdominal symptoms, or abnormal liver tests during prolonged treatment warrant medical review.
Serious skin reactions are rare but possible
Severe reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have also been reported after ivermectin use.
A widespread blistering or peeling rash, sores involving the mouth or eyes, or a severe rash with fever needs urgent medical assessment.
Who Needs Extra Caution With Repeated Ivermectin?
Some people require closer assessment before ivermectin is used repeatedly because the risks can be affected by other infections, medicines, pregnancy, age, or underlying illness.
People exposed to Loa loa
One of the most important safety issues involves Loa loa, another parasitic worm found in parts of West and Central Africa.
People with very high Loa loa microfilarial levels can develop severe neurological complications after ivermectin. The U.S. label recommends pretreatment assessment for loiasis in people with significant exposure to endemic areas.
WHO also modifies onchocerciasis treatment strategies in places where the two parasites occur together.
People taking warfarin
Rare post-marketing reports have described increases in INR—a laboratory measure used to monitor blood clotting—when ivermectin was taken with warfarin.
Anyone using warfarin should therefore make sure the prescribing clinician or pharmacist knows before ivermectin is started.
Pregnancy and breastfeeding
The current U.S. oral ivermectin label states that adequate well-controlled studies in pregnant women are lacking and that safety during pregnancy has not been established. It also notes that small amounts enter human milk.
Treatment decisions during pregnancy or breastfeeding should therefore be made by a clinician who can weigh the risks of the parasitic disease against the uncertainties surrounding medicine exposure.
Older adults and people taking several medicines
Older adults may have more liver, kidney, cardiovascular, or other medical conditions and may be taking several interacting medicines.
The U.S. label recommends particular caution in older patients for these reasons.
A complete medication review becomes increasingly important when treatment is repeated.
Why Is Chronic Self-Treatment Different From Medically Supervised Use?
The benefit of a medicine changes the safety calculation. Taking repeated ivermectin to control a confirmed parasitic infection can have a clear medical purpose; taking it indefinitely without evidence of an infection exposes a person to adverse effects while the expected benefit may be uncertain or absent.
One example is COVID-19. FDA-approved ivermectin tablets treat specific parasitic worm infections, but the FDA has not approved ivermectin for preventing or treating COVID-19.
The same principle applies to other unproven chronic uses.
Several problems can arise with unsupervised long-term treatment:
The underlying condition may have been incorrectly diagnosed.
Persistent symptoms may have a different cause.
A treatable infection may require a different medicine.
Drug interactions may go unnoticed.
Increasing doses can raise toxicity risk.
Veterinary or unregulated products may contain inappropriate concentrations.
Ongoing medication may delay appropriate investigation.
Long-term exposure should therefore have a defined medical objective, an evidence-supported dosing strategy, and a plan for determining whether treatment is still needed.
How Is Safety Managed When Ivermectin Must Be Used Repeatedly?
There is no single monitoring schedule that applies to everyone taking ivermectin. Follow-up should match the infection, frequency of treatment, underlying health conditions, and other medications.
For strongyloidiasis, follow-up testing may be used to confirm that the parasite has cleared rather than continuing treatment automatically. CDC recommends repeat stool examinations 2–4 weeks after treatment in patients with persistent symptoms and initially positive stool testing.
For onchocerciasis, repeated treatment is planned around parasite biology and disease-control programs rather than daily symptom-by-symptom dosing.
Questions to address before repeated or prolonged ivermectin treatment
Safety Question | Why It Matters |
Is there a confirmed or strongly suspected parasitic infection? | Treatment should have a defined indication |
What treatment schedule does the infection actually require? | Annual, intermittent, short-course, and daily regimens have different evidence |
Has the person had exposure to Loa loa-endemic regions? | Heavy Loa loa infection can greatly increase neurological risk |
What other medicines are being taken? | Interactions, including with warfarin, may require review |
Is the patient pregnant or breastfeeding? | Human safety data are limited and treatment requires individual assessment |
Are symptoms improving and has the infection cleared? | Follow-up testing may prevent unnecessary repeat treatment |
Are new neurological, liver, skin, or blood-pressure symptoms developing? | These can signal an important adverse reaction |
Repeated prescriptions should not simply continue by habit. When ivermectin is being used over an extended period, the clinician should periodically reassess whether the original indication remains present and whether the selected schedule is still appropriate.
When Should You Seek Medical Care?
Contact a healthcare professional if you are taking repeated ivermectin and develop persistent dizziness, vomiting, marked weakness, new neurological symptoms, a significant rash, or symptoms suggesting liver problems.
Seek urgent or emergency care for:
Confusion or major changes in alertness
Difficulty walking or severe loss of coordination
Seizures
Fainting or severe low blood pressure
Trouble breathing
Severe facial swelling
A blistering or peeling rash
Yellowing of the skin or eyes with significant illness
Ivermectin overdoses can cause serious neurological and cardiovascular effects.
If you have been taking ivermectin regularly without medical supervision, do not increase the dose because symptoms have persisted. A clinician or pharmacist can review why you are taking it, how frequently it has been used, other medications, and whether testing or an alternative treatment is appropriate.
Conclusion
Taking ivermectin long-term can be appropriate in specific medical settings, but the safest evidence usually involves intermittent, clinician-directed treatment—not indefinite daily or weekly self-medication. People with onchocerciasis may receive ivermectin for many years, while complicated strongyloidiasis can occasionally require repeated or suppressive treatment. These situations do not establish the safety or usefulness of chronic ivermectin for unrelated conditions.
If you are considering repeated ivermectin or are already taking it regularly, have the indication, dose, treatment interval, medications, and potential risks reviewed by a qualified healthcare professional rather than continuing or increasing treatment independently.
Frequently Asked Questions
1. Can you take ivermectin every day long-term?
Daily long-term ivermectin is not the usual treatment for common approved human indications. Daily dosing may be used temporarily for severe disseminated strongyloidiasis, but treatment is guided by parasite testing and clinical response. Indefinite daily self-treatment does not have comparable safety evidence.
2. Can ivermectin be taken repeatedly for years?
Yes, for certain infections. WHO recommends repeated annual ivermectin for 10–15 years in onchocerciasis control programs. However, this means intermittent treatment at defined intervals, not continuous daily exposure, and should not be generalized to unrelated medical conditions.
3. Does ivermectin damage the liver?
Most people receiving standard treatment do not develop serious liver injury, but hepatitis and elevated liver enzymes or bilirubin have been reported after ivermectin use. New jaundice, dark urine, or significant illness during repeated treatment should be medically assessed.
4. Can ivermectin cause neurological side effects?
Yes, although serious neurological reactions are uncommon. Reported effects include severe drowsiness, confusion, disorientation, impaired coordination, seizures, stupor, and coma. Higher doses and certain parasitic coinfections can increase concern, so new neurological symptoms require prompt assessment.
5. Is monthly ivermectin ever prescribed?
Occasionally. U.S. labeling notes that monthly suppressive therapy may help selected immunocompromised patients with difficult extra-intestinal strongyloidiasis. The optimal regimen has not been established in well-controlled studies, so this is a specialized medical situation requiring clinician supervision.
6. Is veterinary ivermectin safe for people if the dose is calculated correctly?
No. Veterinary formulations are designed and tested for animals and can differ substantially in concentration and formulation. The FDA advises people never to use animal ivermectin products; poisoning can cause neurological effects, low blood pressure, seizures, coma, and other serious complications.
Comments